USD
+$0.00
(+0.00%
)At Close (As of Sep 9, 2025)
$22.14B
Market Cap
-
P/E Ratio
-0.15
EPS
$22.80
52 Week High
$12.47
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $8.1B |
Total Revenue | $17B |
Cost Of Revenue | $8.5B |
Costof Goods And Services Sold | $8.5B |
Operating Income | -$303M |
Selling General And Administrative | $1.2B |
Research And Development | $998M |
Operating Expenses | $8.4B |
Investment Income Net | - |
Net Interest Income | -$1.1B |
Interest Income | - |
Interest Expense | $1B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.1B |
Income Before Tax | -$1.3B |
Income Tax Expense | $676M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$2B |
Comprehensive Income Net Of Tax | - |
Ebit | -$282M |
Ebitda | $777M |
Net Income | -$1.6B |
Field | Value (USD) |
---|---|
Total Assets | $39B |
Total Current Assets | $13B |
Cash And Cash Equivalents At Carrying Value | $3.3B |
Cash And Short Term Investments | $3.3B |
Inventory | $3B |
Current Net Receivables | $3.1B |
Total Non Current Assets | $27B |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | $4.4B |
Intangible Assets Excluding Goodwill | $4.4B |
Goodwill | $15B |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $3.2B |
Other Non Current Assets | - |
Total Liabilities | $34B |
Total Current Liabilities | $13B |
Current Accounts Payable | $2.2B |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $1.8B |
Total Non Current Liabilities | $21B |
Capital Lease Obligations | $296M |
Long Term Debt | $16B |
Current Long Term Debt | $1.8B |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $18B |
Other Current Liabilities | $8.8B |
Other Non Current Liabilities | $4B |
Total Shareholder Equity | $5.4B |
Treasury Stock | - |
Retained Earnings | -$15B |
Common Stock | $58M |
Common Stock Shares Outstanding | $1.1B |
Field | Value (USD) |
---|---|
Operating Cashflow | $1.2B |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $1.1B |
Capital Expenditures | $498M |
Change In Receivables | - |
Change In Inventory | $166M |
Profit Loss | - |
Cashflow From Investment | $792M |
Cashflow From Financing | -$1.8B |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$2B |
Field | Value (USD) |
---|---|
Gross Profit | $8.1B |
Total Revenue | $17B |
Cost Of Revenue | $8.5B |
Costof Goods And Services Sold | $8.5B |
Operating Income | -$303M |
Selling General And Administrative | $1.2B |
Research And Development | $998M |
Operating Expenses | $8.4B |
Investment Income Net | - |
Net Interest Income | -$1.1B |
Interest Income | - |
Interest Expense | $1B |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $1.1B |
Income Before Tax | -$1.3B |
Income Tax Expense | $676M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$2B |
Comprehensive Income Net Of Tax | - |
Ebit | -$282M |
Ebitda | $777M |
Net Income | -$1.6B |
Field | Value |
---|---|
Ex Dividend Date | 2017-11-27 |
Declaration Date | None |
Record Date | None |
Payment Date | None |
Amount | 0.085 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.